MangoRx reports H1 2024 revenue up 56% YoY to $377K; shareholders' equity jumps 1,685% to $13.8M

MANGOCEUTICALS, INC.

2024-Q2 EPS reported -$0.19 revenue$377,258

Revenue $377,258 for six months ended June 30, 2024, up 55.92% from $241,959 YoY; gross profit $217,190 (+50.48%).
Shareholders' equity increased to $13,829,445 vs $774,754 at Dec 31, 2023 (+1,685%), largely due to Intramont patent portfolio acquisition in April 2024.
Company plans to launch compounded ODT GLP-1 inhibitors (Semaglutide/Tirzepatide) for weight loss and hormone therapy MOJO (Enclomiphene/pregnenolone).
CEO highlights launch of DEA-approved telemedicine operating system.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.